Hasil Pencarian - Patricia Guyot

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

    Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma oleh Joshua Richter, Peggy L. Lin, Viviana Garcia‐Horton, Patricia Guyot, Erin Singh, Zheng‐Yi Zhou, Mark Sievert, Riley Taiji

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’

    Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-... oleh Mike Bastian, Nick Freemantle, Ana B. Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison

    Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison oleh Thomas Huizinga, Ernest Choy, Amy Praestgaard, Hubert van Hoogstraten, Patrick R. LaFontaine, Patricia Guyot, Daniel Aletaha, Ulf Müller-Ladner, Yoshiya Tanaka, Jeffrey R. Curtis, Roy Fleischmann

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%

    Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50% oleh Nick Freemantle, Yingxin Xu, Florence R. Wilson, Patricia Guyot, Chieh-I Chen, Sam Keeping, Gerasimos Konidaris, Keith Chan, Andreas Kuznik, Kokuvi Atsou, Emily Glowienka, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

    Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer oleh Josephine Louella Feliciano, Dylan McLoone, Yingxin Xu, Ruben G.W. Quek, Andreas Kuznik, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel, Patricia Guyot, Gerasimos Konidaris, Keith Chan, Sam Keeping, Florence R. Wilson, Nick Freemantle

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: